146 related articles for article (PubMed ID: 28081969)
1. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.
Morgeaux S; Poirier B; Ragan CI; Wilkinson D; Arabin U; Guinet-Morlot F; Levis R; Meyer H; Riou P; Shaid S; Volokhov D; Tordo N; Chapsal JM
Vaccine; 2017 Feb; 35(6):966-971. PubMed ID: 28081969
[TBL] [Abstract][Full Text] [Related]
2. G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P
Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
[TBL] [Abstract][Full Text] [Related]
4. Single radial immunodiffusion assays for the standardization of the antigenic content of rabies vaccines.
Ferguson M; Seagroatt V; Schild GC
Dev Biol Stand; 1986; 64():81-6. PubMed ID: 3098607
[TBL] [Abstract][Full Text] [Related]
5. A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use.
Krämer B; Kamphuis E; Hanschmann KM; Milne C; Daas A; Duchow K
Biologicals; 2013 Nov; 41(6):400-6. PubMed ID: 24144483
[TBL] [Abstract][Full Text] [Related]
6. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein.
Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM
J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752
[TBL] [Abstract][Full Text] [Related]
7. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.
Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y
Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162
[TBL] [Abstract][Full Text] [Related]
8. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
[TBL] [Abstract][Full Text] [Related]
9. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody.
Perrin P; Morgeaux S; Sureau P
Biologicals; 1990 Oct; 18(4):321-30. PubMed ID: 2285504
[TBL] [Abstract][Full Text] [Related]
10. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
Jallet C; Tordo N
J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
[TBL] [Abstract][Full Text] [Related]
11. Rabies vaccine standardization: International Collaborative Study for the Characterization of the fifth International Standard for Rabies Vaccine.
Lyng J; Bentzon MW; Ferguson M; Fitzgerald EA
Biologicals; 1992 Dec; 20(4):301-13. PubMed ID: 1305406
[TBL] [Abstract][Full Text] [Related]
12. Use of the single radial immunodiffusion test as a replacement for the NIH mouse potency test for rabies vaccine.
Fitzgerald EA; Needy CF
Dev Biol Stand; 1986; 64():73-9. PubMed ID: 3098606
[TBL] [Abstract][Full Text] [Related]
13. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.
Thraenhart O; Ramakrishnan K
J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705
[TBL] [Abstract][Full Text] [Related]
14. Achieving scientific and regulatory success in implementing non-animal approaches to human and veterinary rabies vaccine testing: A NICEATM and IABS workshop report.
Poston R; Hill R; Allen C; Casey W; Gatewood D; Levis R; Mallet L; Smith D; Srinivas G; Stirling C; Allen D
Biologicals; 2019 Jul; 60():8-14. PubMed ID: 31255474
[TBL] [Abstract][Full Text] [Related]
15. A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines.
Aavula SM; Abhinay G; Nimmagadda SV; Maithal K
J Immunoassay Immunochem; 2017; 38(4):400-410. PubMed ID: 28436708
[TBL] [Abstract][Full Text] [Related]
16. Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay.
Moreira WC; Machado NS; Freitas JFS; Almeida AECC; Moura WC
J Virol Methods; 2019 Feb; 264():31-37. PubMed ID: 30448319
[TBL] [Abstract][Full Text] [Related]
17. A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use.
Abhinay G; Dessain S; Srikanth A; Senthilkumar RL; Vidyasagar P; Praveen A; Chandrasekhar Reddy RV; Swapna Reddy E; Rajendra L
Vaccine; 2014 Jan; 32(2):209-13. PubMed ID: 24262315
[TBL] [Abstract][Full Text] [Related]
18. In vitro potency tests: challenges encountered during method development.
Yomayuza CL; Thiel HJ; König M
Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600
[TBL] [Abstract][Full Text] [Related]
19. Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein.
Nimmagadda SV; Aavula SM; Biradhar N; Rao VS; Shanmugham R; Chandran D; Thirumeni N; Singanallur NB; Villuppanoor SA
Clin Vaccine Immunol; 2010 Aug; 17(8):1261-8. PubMed ID: 20573881
[TBL] [Abstract][Full Text] [Related]
20. The rabies peripheral challenge test: more accurate determination of vaccine potency.
Wunderli PS; Dreesen DW; Miller TJ; Baer GM
Vaccine; 2006 Nov; 24(49-50):7115-23. PubMed ID: 16919854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
